80021870: 22nd Update Frontiers in Research and Clinical Management of Asthma and Allergy: From Bench to Bedside

Click here for a text version of the brochure
Text version of brochure

ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 9.25 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
NURSING CREDITS
ANCC: American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
AANP: American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
OTHER CREDIT
American Academy of Physician Assistants (AAPA)
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Description:
Allergic respiratory diseases have experienced an increased incidence and prevalence over the past decade. Allergic rhinitis now affects 60 million people in the U.S. and asthma, principally defined to be allergic in the majority of patients, is a burden to 24 million people. Allergic rhinitis and asthma represent a major socioeconomic burden to our society, incurring combined direct costs of $16 billion and an additional $10-12 billion in indirect costs. The recent update of the guidelines from the NHLBI, through the National Asthma Education and Prevention Program for the diagnosis and management of asthma, has been widely disseminated and publicized but still has not been effectively implemented in many health care settings across the country. This year’s program will focus on state-of-the-art advances in molecular biology of allergic disease, constructs, including TLR constructs, sublingual immunotherapy, and discussion of rational pharmacotherapy with an emphasis on newly approved therapeutic agents. The conference will take a penetrating look at research on clinical applications for the management of asthma and allergic disease. There will also be roundtable luncheon for faculty and participants to discuss individual cases and clinical problems.

Objectives:
After attending this activity, the participant will demonstrate the ability to:
- Recognize state-of-the-art advances in the molecular biology of allergic disease
- Discuss rational therapeutic decisions in the management of allergy, rhinitis, respiratory disease and asthma
- Apply new therapeutic approaches/diagnosis for allergic disease

Talks

Policy On Speaker And Provider Disclosure

It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.